Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Rubio says U.S. wants to ‘partner’ with countries on hemisphere issues

December 19, 2025

Trump says U.S. drug prices will drop under new deals with pharma companies

December 19, 2025

ChatGPT will now let you pick how nice it is

December 19, 2025

GeeFi (GEE) Celebrates Presale’s Milestones by Announcing New Giveaway to Its Community

December 19, 2025

‘Worst call of my life’: Family of Toronto ‘mass shooting’ victim speak at sentencing

December 19, 2025
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » SNPS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Announces that Synopsys Investors Have Opportunity to Lead Class Action Lawsuit
Press Release

SNPS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Announces that Synopsys Investors Have Opportunity to Lead Class Action Lawsuit

By News RoomDecember 19, 20254 Mins Read
SNPS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Announces that Synopsys Investors Have Opportunity to Lead Class Action Lawsuit
Share
Facebook Twitter LinkedIn Pinterest Email
SNPS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Announces that Synopsys Investors Have Opportunity to Lead Class Action Lawsuit

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Synopsys To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Synopsys between December 4, 2024 and September 9, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Synopsys, Inc. (“Synopsys” or the “Company”) (NASDAQ: SNPS) and reminds investors of the December 30, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the extent to which the Company’s increased focus on artificial intelligence customers, which require additional customization, was deteriorating the economics of its Design IP business; (2) that, as a result, “certain road map and resource decisions” were unlikely to “yield their intended results;” (3) that the foregoing had a material negative impact on financial results; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On September 9, 2025, after market hours, Synopsys released its third quarter 2025 financial results, revealing the Company’s “IP business underperformed expectations.” The Company reported quarterly revenue of $1.740 billion, missing its prior guidance of between $1.755 billion and $1.785 billion, and reported net income of $242.5 million, a 43% year-over-year decline from $425.9 million reported for third quarter 2024. Moreover, the Company reported its Design IP segment accounted for approximately 25% of revenue and came in at $426.6 million, a 7.7% decline year-over-year. Finally, management provided guidance which implied that Design IP revenues will decline by at least 5% on a full-year basis in fiscal 2025.

On this news, Synopsys’s stock price fell $216.59, or 35.8%, to close at $387.78 per share on September 10, 2025, on unusually heavy trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding Synopsys’ conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Synopsys class action, go to www.faruqilaw.com/SNPS or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2fceea32-072d-4e7c-b9fd-7ceadbf788ad

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

GeeFi (GEE) Celebrates Presale’s Milestones by Announcing New Giveaway to Its Community

NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis

MGC’s Next Evolution: From Gaming Token to a Trusted Asset for Cross-Platform Web3 Partnerships

Rocket Lab Awarded $816M Prime Contract to Build Missile- Defense Satellite Constellation for U.S. Space Force

Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Predictu Launches AI-Driven Prediction Market Platform with Leverage Trading

Remedy’s Nutrition® Launches Mega VMT™ High-Potency Multivitamin to Revolutionize Daily Energy and Nutritional Wellness

GeeFi (GEE) Shows Resilience Amid Market Pressure as Its Presale Nears $1.5M Raised in a Few Weeks

Bitget Teams Up with Google Developer Group ETH Zurich to Accelerate Web3 and AI Skills Among Students

Editors Picks

Trump says U.S. drug prices will drop under new deals with pharma companies

December 19, 2025

ChatGPT will now let you pick how nice it is

December 19, 2025

GeeFi (GEE) Celebrates Presale’s Milestones by Announcing New Giveaway to Its Community

December 19, 2025

‘Worst call of my life’: Family of Toronto ‘mass shooting’ victim speak at sentencing

December 19, 2025

Subscribe to News

Get the latest Canada news and updates directly to your inbox.

Latest News

Israel must answer for denying Canadian delegation’s entry, MPs tell Anand

December 19, 2025

Flu hospitalizations nearly double as H3N2 spreads across Canada

December 19, 2025

Google sues web scraper for sucking up search results ‘at an astonishing scale’

December 19, 2025
Facebook X (Twitter) Pinterest TikTok Instagram
© 2025 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version